Treating uveitis with phaco

Article

Phacoemulsification can increase visual acuity in uveitis patients, concluded a study published in the January issue of the British Journal of Ophthalmology.

Phacoemulsification can increase visual acuity in uveitis patients, concluded a study published in the January issue of the British Journal of Ophthalmology.

Susan Lightman of Moorfields Eye Hospital, London, UK and colleagues conducted a retrospective medical record review of uveitis patients (n=101) undergoing phacoemulsification and intraocular lens (IOL) implantation.

Visual acuity was significantly improved (≥2 lines) for 64.4% and 71.3% of patients at first postop and final follow-up visits, respectively. Over six years’ follow-up, slightly more than half of patients doubled their visual angle; this was more prevalent among eyes with preop lesions on either the retina or optic nerve. At three months, postoperative uveitis was most likely to develop in female patients or those with significant perioperative posterior synechiae. Patients with postop uveitis were at increased risk of developing macular oedema.

Thus the team concluded that, although phacoemulsification tends to increase visual acuity in uveitis patients, those patients with macular or optic nerve lesions are more likely to lose visual acuity.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.